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Hepatitis B viruses establish a chronic, productive, and noncytopathic infection of hepatocytes. Viral products are
produced by transcription from multiple copies (5–50) of covalently closed circular (ccc) viral DNA. This cccDNA does
not replicate, but can be replaced by DNA precursors that are synthesized in the cytoplasm. The present study was
carried out to determine if long-term treatment with an inhibitor of viral DNA synthesis would lead to loss of virus
products, including cccDNA, from the liver of woodchucks chronically infected with woodchuck hepatitis virus. Viral
DNA synthesis was inhibited with the nucleoside analog, lamivudine (29-deoxy-39-thiacytidine). Lamivudine treatment
produced a slow but progressive decline in viral titers in serum, to about 0.3% or less of the initial level. However, even
after maintenance of drug therapy for 3–12 months, .95% of the hepatocytes in most animals were still infected.
Significant declines in the percentage of infected hepatocytes and of intrahepatic cccDNA levels were observed in only
three woodchucks, two in the group receiving lamivudine and one in the placebo control group. Moreover, virus titers
eventually rose in woodchucks receiving lamivudine, suggesting that drug-resistant viruses began to spread through the
liver starting at least as early as 9–12 months of treatment. Three types of mutation that may be associated with drug
resistance were found at this time, in a region upstream of the YMDD motif in the active site of the viral reverse
transcriptase. The YMDD motif itself remained unchanged. Not unexpectedly, the lamivudine therapy did not have a
impact on development of liver cancer. © 1998 Academic Press
INTRODUCTION
Hepadnaviruses cause infections of the liver which
can be both chronic and productive in the absence of an
effective response by the host immune system. Such
chronic infection can lead to liver disease, which may
evolve to cirrhosis and hepatocellular carcinoma. Virus
infection is not overtly cytopathic, and every hepatocyte
is probably infected. The cellular injury and death and
the resultant effects on the liver which are observed
during chronic infections are thought to result from the
immune response (Chisari, 1995) to the infected hepato-
cytes.
Hepadnavirus genome replication, mediated by the
viral reverse transcriptase, takes place in the cytoplasm,
within immature viral nucleocapsids (Summers and Ma-
son, 1982). Unlike the retroviruses, hepadnaviruses do
not replicate though transcription of an integrated provi-
ral DNA. Rather, viral RNA synthesis takes place from a
covalently closed circular (ccc) viral DNA localized to the
nucleus of the infected cells (Tuttleman et al., 1986;
Newbold et al., 1995). This DNA does not undergo semi-
conservative replication, but is regenerated by the re-
verse transcription taking place in the cytoplasm (Tuttle-
man et al., 1986). New cccDNA synthesis is needed to
keep pace with loss resulting from hepatocyte death. It is
also possible that cccDNA may undergo spontaneous
degradation, again requiring cccDNA synthesis to main-
tain the chronic infection.
The viral reverse transcriptase is involved in
cccDNA replacement as well as the production of
progeny virus. Thus, it has been hoped that reverse
transcriptase inhibitors would facilitate the gradual
loss of infection, by blocking both virus production and
replacement of cccDNA. But recent cell culture studies
employing primary woodchuck hepatocytes have im-
plied that the spontaneous decay of cccDNA in non-
dividing cells is too slow to lower the steady-state
concentration of this DNA when new viral DNA syn-
thesis is inhibited by lamivudine or dideoxycytidine
treatment for up to 5 weeks (Moraleda et al., 1997).
Thus, as a practical matter, cccDNA loss from the liver
during nucleoside analog therapy appears to require
the death of infected cells. This would directly elimi-
nate viral DNA; additional losses may occur if viral
DNA does not survive through mitosis as infected
hepatocytes divide to replace dying hepatocytes. In
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the uninfected woodchuck liver, hepatocyte death is a
very rare event; cellular life times appear to be at least
6–12 months (Kajino et al., 1994). However, during
chronic liver disease, the rate of cell death may be
considerably elevated. Inhibition of new viral DNA
synthesis in an individual with a hepadnavirus infec-
tion should therefore reduce the intrahepatic levels of
viral DNA, especially cccDNA, at a rate that is related
to the rate of cell death.
In a previous study of the DHBV-infected duck (Fourel
et al., 1994), we found that loss of virus from .90% of
hepatocytes could be achieved even during short-term
therapy if the level of liver injury was sufficiently ele-
vated. In particular, even 1 month of treatment with 29
carbodeoxyguanosine (29CDG) was associated with a
90% decrease in the number of infected hepatocytes, an
effect which appeared to result from a very elevated level
of hepatocyte proliferation (and, by inference, hepatocyte
death) during the first few weeks of 29CDG administra-
tion. By contrast, 3 months of therapy with the nontoxic
antiviral agent FTC was associated with an ca. 60% drop
in cccDNA levels, though without an equivalent decline
in the fraction of infected hepatocytes (Fourel et al.,
1994). This drop in cccDNA levels was about what would
be expected from natural cell turnover in the duck. The
present study was carried out to determine if a greater
loss of virus-infected hepatocytes would occur during
therapy with a nontoxic antiviral agent, if there was a
more active liver disease than in the infected duck, and
if a longer period of treatment was undertaken. For these
studies, we used woodchucks that became chronically
infected with woodchuck hepatitis virus (WHV) following
neonatal inoculation of the virus. As an antiviral agent,
we used lamivudine, which is not known to have signif-
icant liver toxicity (Averett and Mason, 1995; Honkoop et
al., 1997). Moreover, in vitro studies suggest that this
drug should be phosphorylated to the nucleotide in adult
woodchuck liver at a rate 20–60% of that in human liver
(Schinazi et al., 1997).
Treatment of chronically infected woodchucks with
lamivudine reduced virus titers 300-fold or more. How-
ever, in most woodchucks, long-term drug administration
did not produce the desired loss of infected hepatocytes.
Within a year, the predominant drug-sensitive WHV
quasi-species present before therapy were supplanted
in nearly all woodchucks by a population of apparently
drug-resistant virus, as assessed by both a rise in virus
titers and the appearance of amino acid changes in or
near the active site of the viral reverse transcriptase. A
major decline (.90%) in the proportion of infected hepa-
tocytes was observed in only two of nine woodchucks
receiving lamivudine. No statistically significant decline
in the proportion of infected hepatocytes was observed
in the remaining woodchucks. Even in those two in-
stances where a decline occurred, the role of the nucle-
oside therapy was unclear, as a loss of infected hepato-
cytes also occurred in one of eight woodchucks treated
with the placebo. In most woodchucks, drug-resistant
viruses which are either present prior to therapy or arise
spontaneously during therapy may be a major impedi-
ment to virus clearance via long-term nucleoside treat-
ment.
RESULTS
Lamivudine treatment produced a slow but
progressive decline in serum WHV
Woodchucks 300 to 316 (Table 2) were started on a
dose of lamivudine of 40 mg per kg. As illustrated in
Fig. 1 for woodchucks 300–302 (top), this dose of drug
caused only a slight reduction in virus titers in serum.
A second group of woodchucks was started at the
higher dose of 200 mg per kg (Fig. 1). At this concen-
tration, quicker declines in virus titers were observed,
though the rates were still surprisingly slow (Figure 1,
bottom) compared to humans treated with lamivudine
(Nowak et al., 1996). After about 12 weeks, the first
group of woodchucks was shifted from a dose of 40
mg to a dose of 200 mg per kg. Ultimately, virus titers
in all woodchucks, with the exception of 4960 (Table
2), declined at least 300-fold or greater. At this point,
plasma levels of lamivudine were as shown in Table 1.
Variation in virus titers was observed in some wood-
chucks receiving placebo (Table 3). However, in most
woodchucks receiving placebo there was no consis-
tent pattern of change in virus titers. The electro-
phoretic mobility of viral DNA extracted from virus
present in the serum of the animals receiving lamivu-
dine did not vary significantly from that in untreated
woodchucks. There was no evidence at any time dur-
ing lamivudine therapy for the release of virus contain-
ing immature forms of DNA, as was recently described
in a woodchuck receiving acyclovir (Tencza and New-
bold, 1997).
After about 1 year of therapy, virus titers again
TABLE 1
Blood Levels of Lamivudine
Woodchuck No.
Lamivudine concentration (mM)
3 h posttreatment 24 h posttreatment
Infected
4960 139 25
4962 205 128
Uninfected
4409 172 45
4414 141 28
4427 132 8.1
4457 (placebo) Not detected Not detected
Note. Concentrations of lamivudine in plasma collected from wood-
chucks that had been treated for at least 6 months were determined as
previously reported (Frick et al., 1993, 1994).
19WHV INFECTION OF THE LIVER
started to rise in the lamivudine-treated woodchucks,
though usually not to pretreatment levels (Table 2).
The only exception was woodchuck 306, in which virus
replication failed to rebound even 5 months after drug
withdrawal (Tables 2 and 5). This may not have been
drug related, since a similar loss was observed in
woodchuck 5114, which had received the placebo (Ta-
bles 3 and 6).
Mutations of the active site of the WHV reverse
transcriptase are associated with a failure of drug
therapy
Virus with mutations of the conserved YMDD motif in
the active site of the HBV reverse transcriptase, together
with mutations in a region slightly upstream of the YMDD
motif, called the B domain (Bartholomeusz and Locarnini
TABLE 2
Woodchucks Treated with Lamivudine
Note. Treatment was carried out as described under Materials and Methods. The final treatment was done at the time indicated in boldface type.
Virus titers (viral DNA containing particles per ml) were determined as described under Materials and Methods.
a The initial GGT level was determined ca. 1 month before the start of lamivudine administration.
b ND, not done.
c The initial GGT level was determined ca. 2 weeks after the start of lamivudine administration.
Woodchuck
No. of
months of
treatment
Virus titer
(3 1029) GGT
Necropsy:
duration of
treatment (age);
observations
300F 0 7 8a
3 0.8 86 14 months (28)
5 0.03 92 6 cm HCC
7 0.01 NDb
10 0.01 94
11 ,0.01 148
12 0.5 165
13 1.1 221
301M 0 8 8a
3 0.6 13 19 months (35)
5 0.07 13 small HCC
7 0.01 ND
10 0.01 8
11 0.2 9
12 0.7 13
15 0.1 9
17 0.04 11
18 0.007 5
20 5 21
302M 0 10 8a
3 2 11 17 months (31)
5 0.04 9 mult. HCC
7 0.04 ND
10 0.04 8
11 0.4 13
12 0.2 12
15 0.3 127
17 2 253
306F 0 5 8a
3 0.6 29 19 months (38)
5 ,0.01 15 3 cm HCC
7 ,0.01 ND
10 ,0.01 8
12 ,0.01 ND
15 ,0.01 22
17 ,0.01 ND
18 ,0.005 220
24 ,0.005 2072
308F 0 4 41a
3 1 12 19 months (35)
5 0.3 8 Small HCC
7 0.007 ND
Woodchuck
No. of
months of
treatment
Virus titer
(3 1029) GGT
Necropsy:
duration of
treatment (age);
observations
308F 10 0.007 8
11 ,0.01 9
12 0.02 9
15 0.3 15
18 4 25
20 5 28
315M 0 7 55a
3 0.6 17 19 months (35)
5 0.07 16 2 cm HCC
7 0.02 ND
10 0.01 8
11 ,0.01 26
12 ,0.008 ND
13 0.02 23
15 0.06 32
17 6 ND
18 2 23
20 3 61
316F 0 16 8a
3 0.2 111 12 months (26)
5 ,0.02 229 mult. HCC
7 ,0.02 ND
10 ,0.02 65
11 ,0.02 49
4960F 0 2 9c
3 0.04 47 16 months (33)
5 0.07 8 2 small HCC
7 0.09 8
10 13 13
13 6 28
16 1 45
18 2 29
4962M 0 3 12c
3 ,0.01 11 16 months (33)
5 ,0.01 8 no HCC
7 ,0.01 19
10 2 13
13 1 21
15 0.5 15
16 0.04 9
18 4 8
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(1997) for review), become predominant in the serum if
virus titers start to rise toward pretreatment levels in HBV
patients receiving lamivudine therapy (Ling et al., 1996;
Tipples et al., 1996; Bartholomew et al., 1997). While the
altered YMDD motif is probably sufficient to create some
degree of drug resistance (Fischer and Tyrrell, 1996),
resistance appears to be greater when the YMDD muta-
tions are combined with mutations in the B domain (Allen
et al., 1997). In contrast, mutations of the B domain, in the
absence of mutations of the YMDD motif, have been
associated with resistance to famciclovir in HBV patients
(Bartholomeusz and Locarnini, 1997). To determine if
virus with alterations in either of these two domains was
associated with the failure of drug therapy in the lami-
vudine-treated woodchucks, a region spanning both do-
mains was PCR amplified from virion DNA and directly
sequenced. Assuming that the PCR primers bind equally
well to all templates and that there is no size variation
between quasispecies, this approach should reveal the
sequence of the most abundant viral genomes. The re-
sults are summarized in Fig. 2, which shows the se-
quence before therapy (E) and after 13–15 months of
continuous therapy (L). Virus with three different classes
of mutation in the vicinity of the B domain, but not of the
YMDD motif, was prevalent in all woodchucks in which
virus titers had rebounded after a transitory suppression
by lamivudine (no change was evident in viral DNA that
was PCR amplified from serum of woodchuck 306; cf.
Fig. 2 and Table 2). The mutations were not present in the
virus population that was predominant before therapy,
nor in virus collected from woodchucks receiving a pla-
cebo. However, sequence analysis suggested that a shift
in the prevalent virus could occur over time even in the
absence of drug therapy. One woodchuck (4961) receiv-
ing the placebo showed a change in the B domain, with
the alanine at position 565 changed to a serine. This
change was also seen in woodchucks 300 and 308, but
accompanied by a leucine (L) to methionine (M) change
at position 564 and a serine (S) to asparagine (N) change
at 569. In other treated woodchucks, an additional
change was detected at amino acid 510, upstream of the
B domain (Fig. 2); however, the pattern of this change in
different woodchucks did not reveal a clear association
with the evolution of drug resistance. Variations at the B
domain in lamivudine-treated woodchucks did not show
any obvious correlation with the virus inoculum used for
neonatal infection of the woodchucks.
The alanine (A) to threonine (T) change at amino acid
565 in the B domain of the reverse transcriptase (wood-
chucks 301, 302, 4960, 4962) was associated with a
nucleotide change which introduces a stop codon in the
overlapping S gene (Fig. 3). This mutation would truncate
the carboxy terminus of the three viral envelope proteins
S, L, and M by 55 amino acids. This suggests that the
mutant virus must coexist in hepatocytes along with virus
which retains the wild-type envelope gene sequence.
This possibility was consistent with the sequencing data,
which suggested a minor population of virus with a
wild-type sequence in this region, as summarized in Fig.
3. More importantly, the prevalence of virus with an
envelope mutation that would confer a replication defect
supports the idea that the pol gene mutation was the
important one and that it conferred drug resistance. The
coexistence in serum of a majority population of mutant
virus with a minor population of wild-type virus was also
consistent with the earlier reports that the viral RT pref-
erentially packages its own pregenome into subviral
particles (Bartenschlager et al., 1990; Hirsch et al., 1991).
Finally, 11 of 12 viral clones from a preparation of
cccDNA from a liver biopsy of woodchuck 302, taken
when virus titers first rebounded (Table 2), were of the
wild-type sequence in the B domain, even when the
mutant virus predominated in the serum (T. Zhou, C.
Aldrich, W. Mason, unpublished observations), an obser-
vation which is again consistent with the idea that the B
domain mutations conferred the drug resistance.
A dramatic loss of virus-infected hepatocytes was not
observed in the majority of lamivudine-treated
woodchucks
The fraction of infected hepatocytes in liver biopsy
specimens was estimated by immunoperoxidase stain-
ing and light microscopy to detect viral core antigen and
in situ hybridization (ISH) to detect viral nucleic acids.
FIG. 1. Decline in virus titers in woodchucks treated with two different
doses of lamivudine. Virus titers (virions/ml) were determined by mea-
suring levels of viral DNA, as described under Materials and Methods.
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Loss of viral nucleic acids was assessed by Southern
blot assays for total and cccDNAs. Changes in liver
disease activity were subsequently assayed by his-
topathologic evaluation and by estimation of increased
hepatocyte turnover, via PCNA staining for hepatocytes
which have entered the cell cycle. The results are sum-
marized in Tables 4–6. Two biopsies were available dur-
ing the time when virus replication was suppressed, the
first taken within a month or so after maximum suppres-
sion was achieved, the other just as virus titers were
starting to rise. In the majority of lamivudine-treated
woodchucks, the amount of replicative intermediate DNA
(Mason et al., 1982) in the liver had dropped 3- to 10-fold
after 3–6 months of therapy, compared to an ca. 2-fold
decline in woodchucks receiving placebo. Modest de-
clines in cccDNA levels were noted in some wood-
chucks, but in only three woodchucks, discussed below,
was there a significant decline. In general, the amounts
of replicative intermediate DNA had begun to rise slightly
again after 10 to 12 months of therapy. The exceptions
among the lamivudine-treated woodchucks were 306
and 315, in which viral DNAs in the liver dropped to
nearly undetectable levels by 12 months (Table 5).
In agreement with the DNA data, the fraction of in-
fected hepatocytes did not decline appreciably from the
.95% level characteristic of untreated animals. In most
treated woodchucks the intensity of the signals for cyto-
plasmic WHV core antigen and nucleic acids were re-
duced compared to the pretreatment biopsy even though
the number of infected hepatocytes did not decrease.
Prior to therapy as well as in the woodchucks receiving
placebo, higher amounts of cytoplasmic core antigen
and viral nucleic acids were detected in lobular zone 1
(periportal) compared to zone 3 (centrilobular) hepato-
TABLE 3
Placebo Controls
Note. The final treatment was done at the time indicated in bold type.
a The initial level of GGT was determined ca. 1 month before the start of placebo administration.
b Not done.
c The initial level of GGT was determined ca. 2 weeks after the start of placebo administration.
Woodchuck
No. of
months of
treatment
Virus titer
(31029) GGT
Necropsy:
Duration of
treatment (age);
observations
307M 0 2 8a
3 2 15 18 months (32)
5 0.4 26 large HCC
7 0.5 NDb
10 0.4 52
12 192
13 0.4 126
15 0.2 269
18 0.6 1047
309F 0 9 11a
3 5 44 10 months (24)
5 5 24 massive HCC
7 3 ND
10 10 82
310M 0 1 8a
3 0.8 67 18 months (35)
5 0.4 ND no HCC
7 0.2 ND
10 1 8
13 0.8 17
15 1 11
18 1 15
20 ND 11
313F 0 7 8a
3 3 26 11 months (25)
5 2 40 pneumonia;
7 2 ND no HCC
10 0.7 55
11 0.3 96
314F 0 7 14a
3 3 17 17 months (31)
5 2 17 mult. HCC
Woodchuck
No. of
months of
treatment
Virus titer
(31029) GGT
Necropsy:
Duration of
treatment (age);
observations
314F 7 2 ND
10 4 10
13 14 52
15 6 160
4961F 0 3 8
3 1 ND 16 months (35)
5 0.9 9 mult. HCC
7 2 9
11 2 12
13 0.3 119
16 0.5 143
18 0.3 112
5114M 0 10 43c
3 0.5 ND 16 months (35)
5 0.7 8 2 cm HCC
7 4 8
10 0.03 42
11 0.04 17
12 2
13 4 29
15 ,0.01
16 ,0.01 28
18 ,0.01 147
5154F 0 6 10d
3 4 ND 16 months (33)
5 4 8 HCC
7 3 9
10 4 69
11 18 150
13 ND 490
16 3 274
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cytes and, in most woodchucks, the lobular distribution
of these markers was not affected by treatment with
lamivudine. Again, the exceptions were 306 and 315. In
woodchuck 306, infected cells were no longer detected
and, in 315, only about 2–5% still expressed detectable
levels of virus core antigen and nucleic acids (Fig. 4).
One of these woodchucks (306) also displayed the high-
est level of PCNA-positive hepatocyte nuclei prior to
therapy, but this correlation was not evident for wood-
chucks 315 and 5114, which also showed a dramatic
clearance of the infection in liver biopsies taken after
10–12 months of lamivudine or placebo administration,
respectively (Fig. 4; Tables 5 and 6). For woodchucks 315
(Table 2) and 5114 (Table 3), virus production rebounded
after partial clearance of virus from the liver; a second
cycle of clearance from serum and liver was then ob-
served in woodchuck 5114 (Table 6). Thus, at least part of
the antiviral activity observed in woodchucks 306 and
315 may be due to a spontaneous antiviral host re-
sponse, rather than to a therapeutic effect of the drug.
Pathological assessment
Minimal liver inflammation or injury up to the last biopsy
characterized livers from seven of eight uninfected wood-
chucks (Table 4). At the last biopsy two of these animals
(4409, 4467) had a slight increase in liver inflammation and
a fourth had a significant level of liver injury (351). One of
these animals had pneumonia and hepatic abcessation
(4409), but the cause for the increase in inflammation at the
end of the study was not apparent. The histologic appear-
ance of other organs was not abnormal. One animal (353)
had moderate levels of hepatic inflammation throughout the
study. PCNA labeling and the degree of liver injury did not
show any consistent relationship.
Minimal to mild hepatitis was consistently evident in
WHV-infected lamivudine-treated woodchucks, but var-
ied very little during the course of therapy (Table 5). The
degree of inflammation did not seem to be significantly
affected by drug-induced changes in WHV levels in se-
rum or liver. There was no evidence of drug-induced
hepatic toxicity in any of the treated animals at any time
in the course of the study. The proportion of PCNA-
labeled hepatocytes was related in the liver injury score
to the extent that in 8 of the 11 instances that the PCNA
labeling was 1% or greater the liver injury score was at
least 1. However, as seen in the uninfected animals, not
all scores of 1 or greater were associated with increased
PCNA labeling.
FIG. 2. Appearance of viral RT mutations in woodchucks treated with lamivudine. To assay for RT mutations in the WHV present in woodchucks
in which virus titers had arisen to near pretreatment levels, a region (528 nt) spanning the YMDD motif of RT was PCR amplified and sequenced.
Predicted amino acid sequences are numbered from the first AUG of the WHV RT gene. The amino acid sequence shown at the top was obtained
from GenBank (Accession No. M19183) (Cohen et al., 1988) and starts with amino acid 502 in the polymerase open reading frame. For each
woodchuck, sequences were determined for the virus population present before therapy (E) and after 13 months (woodchucks 4960, 4961, 4962, 5114,
5154) or 15 months of therapy (L). Treated woodchucks (300 through 4962) are shown at the top. Matched samples from woodchucks receiving the
placebo are shown at the bottom. No sequence changes for the prevalent virus population were noted in woodchuck 306, in agreement with the
observation that virus production did not rebound during therapy.
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Liver injury scores in placebo-treated WHV-infected
animals were similar to those in the lamivudine-treated
animals (Table 6). The correlation between PCNA label-
ing and liver injury in this group was similar to the other.
Six of 9 biopsies with 1% of hepatocytes labeled with
PCNA had liver injury scores of at least 1. Among the 17
WHV-infected woodchucks surviving to at least 2 years
of age, 14 had grossly evident liver tumors at necropsy
(Tables 2–3). Only 1 treated woodchuck (4962) and 2
placebo-treated animals (310, 313) appeared tumor free.
One of these animals (313) died of pneumonia at 11
months of treatment. No liver tumors were observed in
the 5 uninfected animals that were necropsied after 30
months of treatment (Table 4). Five animals were eutha-
nized after becoming moribund as a consequence of
HCC, including 302, 307, 309, 314, and 316 (Tables 2 and
3). As expected (Abe et al., 1988), persistently elevated
GGT levels had developed in most but not all of the
infected woodchucks which were subsequently found, at
necropsy, to have hepatocellular carcinoma (e.g., wood-
chuck 306, Table 2; cf. Tables 2–4).
As noted above, it was surprising that the liver injury
scores (Tables 4–6) were not a better reflection of the
incidence of PCNA-positive hepatocytes; for instance,
variations of 5- to 10-fold in the PCNA staining frequency
from biopsy to biopsy were not necessarily accompanied
FIG. 3. Mutations of the B domain of WHV RT also produce changes in the overlapping envelope gene. The nucleotide sequences of the WHV
envelope gene as well as predicted changes in coding are shown in the region overlapping the B domain of the viral RT and compared with a
sequence obtained from GenBank (Cohen et al., 1988). As shown, for woodchucks 300–302, 4960, and 4962, the sequence ladders of the second
sample suggested that the prevalent virus population was a mixture of mutant with a smaller amount of wild-type WHV. Nucleotides are numbered
according to Cohen et al. (1988).
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TABLE 4
Uninfected Woodchucks
Woodchuck
(treatment)
No. of months
of treatment
PCNA-positive
hepatocytes (%)
Liver
injury
scorea
GGT
(serum)
Necropsy:
duration of
treatment (age);
observations
351M (lamivudine) 25 0.09 1/2 8
0 8b
1 0.09 1/2
3 10 18 months (35)
5 0.08 1/2 27 no HCC
12 12
18 5
20 2.1 21 5
4409M (lamivudine) 22 0.02 0 9
0 16c
3 0.02 1/2 10 7 months (24)
5 8 lung abscess
7 0.07 1 8 no HCC
4414M (lamivudine) 22 0.02 1/2 9
0 22c
3 0.04 0 5 16 monthsd
5 8
7 8
10 0.05 1/2 10
16 5
18 1/2 5
4427F (lamivudine) 22 0.01 0 16
0 19c
3 0.03 0 19 16 monthsd
5 21
7 14
10 0.3 0 22
16 11
18 14
353F (placebo) 25 0.03 1 10
0 18b
1 0.05 1/2
3 10 16 months (30)
5 0.07 8 no HCC
8 8
12 0.02 1 10
16 ND 1 7
4434F (placebo) 22 0.02 0 11
0 23c
3 ,0.02 0 7 16 monthsd
5 8
7 11
10 ,0.02 0 14
12 19
16 5
18 5
4457M (placebo) 22 0.03 1/2 10
0 25c
3 0.03 1/2 9 5 months (26)
5 8 no HCC
7 1.2 1/2 ND
4467F (placebo) 22 0.02 0 10
0 11c
3 0.01 0 9 16 months (35)
5 8 no HCC
7 8
10 0.01 1/2 9
12 10
16 5
18 ND 1 10
a Liver injury was assessed as described under Materials and Methods.
b This GGT level was determined ca. 1 month before the start of lamivudine administration.
c This GGT level was determined ca. 2 weeks after the start of lamivudine administration.
d Still alive at 3.5 years of age.
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by a change in the liver injury score. Assuming that
PCNA expression in the nucleus is an indicator of the
passage of hepatocytes through the cell cycle leading to
cell division, and not just of their entry into the cycle, this
implies that the extent of hepatocyte death and replace-
ment does not always have a simple, direct correlation
with other indicators of liver injury in infected wood-
chucks. Nonetheless, the highest incidence of PCNA-
positive hepatocytes, averaged over several biopsies,
was observed in woodchuck 306, the one lamivudine-
TABLE 5
Woodchucks Treated with Lamivudine
Woodchuck
No. of
months of
treatment
Total DNAa
(copies/hep)
CCC DNAa
(copies/hep)
Percentage
virus-positive
hepatocytesb,c
Liver injury
score
Percentage
PCNA-positive
hepatocytes (%)
300F 25 2900 54c .95 1/2 0.4
1 1000 20 .95e 1 0.8
6 180 14 .95e 1 0.3
12 290 16 .95e 1/2 0.3
301M 25 1400 10 .95 1 0.6
1 1000 11 .95 1/2 0.2
6 100 5 .95 1 0.2
12 590 5 .95 1/2 0.6
18 570 5 .75 1 1.0
20 2100 24 .95 1 1.3
302M 25 850 30 .95 1 0.5
1 1920 26 .95 1 0.4
6 90 8 .95 11 0.3
12 280 11 .95 1 0.08
18 710 8 ND 1 ND
306F 25 680 11 .95 1 0.2
1 41 1.3 .95e 1 3.5
6 12 1.4 .95e 1 1.3
12 ,0.7d ,0.4d ,0.1e 1/2 2.5
18 ND ND ,0.1 1/2 0.2
24 ,10 ,0.3 ,0.1 ND 0.4
308F 25 190 12 .95 1/2 0.06
1 170 3.3 .95e 1/2 0.3
6 90 3.6 .95e 11 0.2
12 60 3.3 .90e 1/2 0.05
18 ND ND .95 1 1.3
20 1490 25 .90 1 0.5
315M 21 1660 14 .95 1/2 3.1
5 1110 5 .95e 1/2 0.2
12 ,10 ,3 2–5e 1/2 0.6
18 1220 35 90 1 1.4
20 1610 120 90 1 1.0
316F 21 680 22 .95 1 ND
5 50 1.6 .95 1 ND
12 240 18 .95 1/2 ND
4960F 21 2500 24 .95 1 0.3
3 790 1.7 .95e 1/2 0.04
10 2900 12.9 .95e 0 0.04
16 720 11 ND 1 0.5
18 2200 40 .90 2 0.6
4962M 21 740 24 .95 1/2 0.3
3 210 18.2 .95 1/2 ND
10 670 8.7 .95 1/2 0.5
16 730 6 ND 1/2 1.5
18 1400 15 .90 1 3.7
a Copy numbers are calculated on the assumption that hepatocytes constitute 70% of liver cell mass.
b Individual hepatocytes were scored both by WHV core antigen staining and in situ hybridization for viral nucleic acids, with similar results.
c In liver biopsy tissue from WHV carrier woodchucks, higher amounts of cytoplasmic WHV core antigen and nucleic acids were detected in zone
1 (periportal) compared to zone 3 hepatocytes (centrilobular). In most woodchucks, the lobular distribution of markers of WHV infection was not
affected by treatment with 3TC.
d Not done.
e The intensity of cytoplasmic WHV core antigen and nucleic acids was reduced compared to the pretreatment biopsy.
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FIG. 4. Loss of infected hepatocytes in lamivudine- and placebo-treated woodchucks. Viral nucleic acids were detected in EAA-fixed liver tissue
by ISH using a digoxigenin–dUMP-labeled DNA probe as described under Materials and Methods. (A and B) Woodchuck 306 before and after 12
months of lamivudine. (C and D) Woodchuck 315 before and after 12 months of lamivudine. (E and F) Woodchuck 5114 before and after 10 months
of placebo. Counterstained with hematoxylin; final magnification, 803.
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treated woodchuck that showed a long-term remission of
virus production and in which virus with alterations of the
polymerase B domain were not detected (cf., Table 2 and
Fig. 2).
DISCUSSION
The evidence that is available indicates that the de-
gree and duration of inhibition of WHV replication that we
were able to achieve in lamivudine-treated woodchucks
was insufficient to significantly lower the number of vi-
rus-infected hepatocytes. A major question in undertak-
ing this antiviral trial had been whether or not either
prolonged drug administration or a combination of ther-
apy and the host’s own immune response to WHV would
lead to substantial clearance of virus from the liver. The
latter possibility seemed reasonable, since the PCNA
staining data suggested that liver cells in chronically
infected woodchucks might have a half-life of about 3
months or less, much shorter than in the uninfected
woodchuck. Such a shortened half-life would lead to a
reasonably rapid and predictable rate of virus loss even
in the absence of spontaneous degradation of cccDNA
or of secretion or degradation of replicative intermedi-
ates present in the cytoplasm. Unfortunately, drug resis-
tance became an obvious problem in nearly all of the
woodchucks after 10–12 months of therapy, when virus
titers in the serum again began to rise. Maximum sup-
pression of virus production was only sustained in most
woodchucks for about 8 months. Within this time span,
liver biopsies were taken about 7 months apart, about 1
TABLE 6
Woodchucks Receiving Placebo
Woodchuck
No. of
months of
therapy
Total DNAa
(copies/hep)
CCC DNAa
(copies/hep)
Percentage
positive
hepatocytesb,c
Liver
injury
score
PCNA-positive
hepatocytes (%)
307m 25 700 15 .95 1/2 0.1
1 630 12 .95 0 1.3
5 320 6 .95 11 0.5
12 130 2.6 .95 1 0.2
18 620 7 ND 1 0.3
309F 25 390 19 .95 1 1.4
1 600 25 .95 1 0.5
5 380 16 .95 1 1.3
310M 25 810 14 .95 1 0.2
1 200 11 .95 1 1.2
5 310 9 .95 1 0.7
12 230 12 .95 1 1.2
20 130 5 ND 2 2.9
313F 25 1100 23 .95 1 0.3
1 1070 13 .95 1/2 0.6
5 610 23 .95 1 0.9
11 ND ND ND ND
314F 25 1200 5 .95 1 0.06
1 650 7 .95 1/2 0.7
5 330 8 .95 1 0.8
12 190 6 .95 1/2 0.8
17 ND ND ND 2 ND
4961F 22 740 28 .95 1/2 1
3 760 43 .95 1/2 0.1
10 2700 23 .95 1/2 0.3
18 650 8 .95 1 0.8
5114M 22 520 16 .95 1/2 0.7
3 140 8 .95 0 1.1
10 10 ,0.6 2 1/2 0.2
18 ,10 ,0.6 ,0.1 1 0.4
5154F 22 1500 25 .95 0 0.6
3 1800 38 .95 0 0.6
10 2500 38 .95 1/2 0.9
16 1300 44 .95 1 1.2
a Copy numbers were calculated on the assumption that hepatocytes constitute 70% of liver cell mass.
b Individual hepatoytes were scored both by WHV core antigen staining and in situ hybridization for viral nucleic acids, with similar results.
c In liver biopsy tissue from WHV carrier woodchucks, higher amounts of cytoplasmic WHV core antigen and nucleic acids were detected in zone
1 (periportal) compared to zone 3 hepatocytes (perilobular).
d Not done.
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month after maximum suppression was achieved and 7
months later, at a time, coincidentally, when virus titers
were beginning. At neither time was there evidence, in
most woodchucks, of a major decline in the number of
infected hepatocytes, from the virtually 100% character-
istic of chronically infected animals. However, we cannot
rule out the possibility that a major decline occurred in
the interval between the biopsies. Nonetheless, this
seems unlikely, since virtually all of the hepatocytes still
remained infected in two woodchucks, 308 and 316, in
which virus titers were still suppressed at the time of the
latter biopsy (Tables 2 and 5).
A surprising finding was that drug resistance ap-
peared so rapidly. This was unexpected because the
infected cell population is relatively stable and all poten-
tial targets are presumably infected; thus, replication of
newly arising variants would be limited by the absence of
new targets for infection. This contrasts to the situation
in HIV patients, where evolution of drug-resistant virus is
apparently facilitated by the rapid turnover of the major
target cell population for virus replication (Ho et al., 1995;
Wei et al., 1995; Finzi et al., 1997; Wong et al., 1997). A
simple hypothesis to explain our observation is that a
large amount of drug-resistant virus exists as a quasi-
species among native WHV populations, but that its
spread is limited because the vast majority of hepato-
cytes are already infected by wild-type virus. Thus, drug-
resistant virus should be a predominant species in the
serum once maximal suppression of replication is
achieved by the drug. Its spread through the liver should
only be possible, however, as the suppression of repli-
cation of the wild-type virus, in combination with hepa-
tocyte proliferation, lowers the level of wild-type DNA,
and hence of superinfection resistance produced by the
wild type, within the liver. In support of the first part of this
hypothesis, we have found in a recent study that in some
lamivudine-treated woodchucks, the appearance of the
apparently drug-resistant virus as the predominant spe-
cies in the serum, as revealed by DNA sequence anal-
yses like those in Fig. 2, can precede the rise in (mutant)
virus titers by several months (Zhou and Mason, unpub-
lished observations).
A second unexpected finding from the study was the
clearance, or partial reduction, in infected hepatocytes
from the livers of three different chronically infected
woodchucks. The observation of partial reduction, re-
bound, and clearance in one of the woodchucks receiv-
ing placebo (5114, Tables 3 and 6; Fig. 4) suggests, but
does not prove, that the transitory clearance observed in
woodchuck 315 and the prolonged clearance observed
in 306 were due to the host immune response rather than
to the antiviral therapy. It is possible, of course, that
continued therapy in woodchuck 306 was responsible for
the sustained response. There is clear evidence that
lamivudine therapy in HBV carriers can lead to a tempo-
rary normalization of serum levels of liver enzymes and
that it probably contributes to virus clearance in some
patients (Tyrrell et al., 1994; Dienstag et al., 1995; Ling et
al., 1996; Nowak et al., 1996; Tipples et al., 1996; Allen et
al., 1997; Bartholomew et al., 1997); however, it appears
that spontaneous HBV clearance from the liver is, as in
the woodchucks, a rare event, and that virus clearance
depends ultimately on the strength of the host immune
response to the virus. Similarly, interferon-a treatment
can lead to clearance of replicating HBV in some pa-
tients (Perrillo et al., 1990), though it remains unclear if
this is due to induction of a qualitative change in the
immune response or simply to the early initiation of a
process that would ultimately occur in these patients in
any case (Evans et al., 1997; Hoofnagle and DiBisceglie,
1997). Unfortunately, it is not yet clear how the immune
system can resolve a transient hepadnavirus infection,
much less how to make a qualitative change in the
immune system of a chronic carrier that would lead to
virus clearance. In HBV transgenic mice a transient
clearance of replicating virus can be induced by TNF-a
and interferon-g and/or -a, and perhaps by other cyto-
kines (Guidotti et al., 1996a,b; Mancini et al., 1996; Ca-
vanaugh et al., 1997). If this has a parallel in the clear-
ance of natural infections, it could be exploited as part of
an antiviral therapy.
Finally, long-term lamivudine administration did not
affect the development of hepatic neoplasms in chroni-
cally WHV-infected woodchucks. The effect of anti-viral
drug treatment may have been diminished by the fact
that these animals had been chronically infected for
more than a year (13–16 months) before they were treat-
ed; an additional factor was that suppression of virus
production was not associated in most woodchucks with
a reduction in the number of infected cells. Moreover,
even short-term infection with WHV can increase the risk
of liver cancer, since woodchucks that have recovered
from WHV infection have an increased risk for liver can-
cer compared to uninfected animals (Korba et al., 1989).
A more efficacious therapy, started at an earlier age,
might still create a significant reduction in liver cancer
incidence. Most likely, better efficacy will depend on the
use of multiple antivirals to reduce the risk of drug-
resistant virus. Other nucleosides are currently under
evaluation for anti-hepadnavirus therapy (Luscombe et
al., 1996; Aguesse-Germon et al., 1997; Innaimo et al.,
1997), though whether combined therapy will slow the
emergence of drug-resistant variants remains to be de-
termined.
MATERIALS AND METHODS
Woodchucks
Woodchucks were housed within the laboratory ani-
mal facility of the Fox Chase Cancer Center. Experiments
with woodchucks were reviewed and approved by the
Institutional Animal Care and Use Committee. Captive
born woodchucks 300–302, 306–310, 313–316, 351, and
353 were acquired from Northeastern Wildlife (South
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Plymouth, NY). Woodchucks 4060–4062, 4067, 4409,
4414, 4427, 4434, 4457, 4467, 5114, and 5154 were from
the woodchuck breeding colony at Cornell University.
Chronic infection was achieved by neonatal inoculation
with serum from WHV-infected woodchucks. Wood-
chucks from Cornell received a subcutaneous inocula-
tion with 100 ml of virus pool 7 (Popper et al., 1987; Gerin
et al., 1989; Miller et al., 1990) (5114; 5154) or 8 (Chen et
al., 1992) (4960–4962, 4967), each of which contains 5 3
106 woodchuck infectious doses of WHV. Woodchucks
from Northeastern Wildlife were inoculated with 0.3 ml of
WHV-positive serum pools prepared at Fox Chase.
Woodchucks 300–302 and 309 were inoculated with dis-
tinct serum pools from woodchucks 306–308, 310, and
313–316. Both pools contained about 109 virus particles
per ml; the specific infectivity of these pools is not
known. Woodchucks 351 and 353, included among the
uninfected group for the purposes of this study, had
undergone neonatal inoculation but did not develop a
chronic infection. None of the remaining uninfected
woodchucks had a history of WHV infection. An addi-
tional four WHV-infected woodchucks (two placebo; two
lamivudine treated) were originally included in the study,
but died or were euthanized during the first few months
and are not included in the presentation. In one treated
animal and one placebo, large HCCs had developed. An
additional lamivudine-treated woodchuck died during
anesthesia. The cause of death in the fourth animal was
not apparent.
Oral administration of lamivudine was carried out once
per day, between 6 and 10 AM. Initially, the woodchucks
received a lamivudine dose of 40 mg per kg using a solu-
tion of 20 mg per ml in 75% Karo syrup. Placebo-treated
animals received the same weight-adjusted dose of the
vehicle. Animals were subsequently switched to a dose of
200 mg per kg administered as a suspension at 100 mg
lamivudine, 280 mg sucrose, 270 mg Dyets Woodchuck
Control Diet (Dyets, Inc., Bethlehem, PA) per ml (w/v), with
the placebo group again receiving a weight-adjusted dose
of the vehicle. The woodchucks from Cornell University
were started on lamivudine at the higher dose. Therapy in
the former group began at about 13 months of age and, in
the latter, at about 16 months of age.
Analysis of viral DNAs
Protocols for liver biopsy and blood collection were
previously described (Kajino et al., 1994). Blood was
collected approximately 1 h after drug administration.
Extraction and Southern blot analysis of viral DNAs in
serum virus and in liver were carried out essentially as in
the earlier study (Kajino et al., 1994). Following hybrid-
ization of blots with a 32P-labeled DNA probe spanning
the entire viral genome, bound radioactivity was mea-
sured using a Fuji Image Analyzer. Amounts of viral DNA
were determined by reference to a known amount of
cloned viral DNA included on each gel.
For PCR amplification of serum virus DNA, virus was
first collected from 50 ml of serum by centrifugation
through a 4-ml step gradient of 10–20% sucrose in 0.15 M
NaCl, 0.02 M Tris–HCl (pH 7.5) for 3 h at 50,000 rpm in an
SW-60 rotor (Beckman) at 4°C. Virus pellets were resus-
pended in 200 ml of 0.1 M NaCl, 0.01 M Tris–HCl (pH 7.5),
0.01 M EDTA, 0.2% (w/v) SDS, 1 mg pronase per ml, and
incubated for 1 h at 37°C. The samples were then ex-
tracted three times with phenol:chloroform (1:1) and the
DNA was collected by ethanol precipitation. Approxi-
mately 10% of the sample was then used for PCR ampli-
fication with Taq DNA polymerase, carried out for 30
cycles of 1 min at 94°C, 1 min at 52°C, and 2 min at
72°C. The forward primer sequence was 59-AGATTGGT-
TGGTGCACTTCT-39 (nt 385 to 403) according to the num-
bering system of Kodama et al. (1985) and the reverse
primer was 59-AATTGTCAGTGCCCAACA-39 (nt 1468 to
1451). The PCR product was gel purified and sequenced.
Automated sequencing was carried out using 59-GGAT-
GTATCTGCGGCGTTT-39 (nt 510 to 528) as the sense
primer and 59-CCCAAATCAAGAAAAACAGAACA-39 (nt
953 to 931) as the antisense primer.
Immunoperoxidase staining, in situ hybridization, and
histopathology of tissue sections
Liver biopsy specimens for immunoperoxidase stain-
ing and ISH were fixed in ethanol:acetic acid (EAA, 1:3)
for 20 min at 4°C and then overnight at 4°C with 100%
ethanol. Specimens for histopathology were fixed in 10%
neutral buffered formalin overnight. Further details of
tissue fixation and processing have been described pre-
viously (Jilbert et al., 1992). For detection of WHV core
antigen by immunoperoxidase staining, tissues were in-
cubated with rabbit serum reactive to WHV core protein
produced in Escherichia coli (a gift from Christoph See-
ger, Fox Chase Cancer Center) (Kajino et al., 1994). PCNA
in hepatocyte nuclei was detected in ethanol:acetic acid
fixed tissue using a mouse monoclonal antibody (PC10)
obtained from DAKO Corp. (Carpenteria, CA), followed by
reaction with biotinylated secondary antibody and
streptavidin–peroxidase complex. Following develop-
ment, immunoperoxidase-stained sections were coun-
terstained with hematoxylin, dehydrated in ethanol, and
mounted in depex. The incidence of hepatocytes with
PCNA-positive nuclei was determined by scoring ap-
proximately 10,000–20,000 hepatocytes on a single liver
tissue section from each woodchuck liver biopsy. Be-
cause of the low numbers of positive hepatocytes in
uninfected liver, precise estimates for the incidence of
PCNA-positive hepatocytes were not obtained.
Viral nucleic acids were detected in EAA fixed sec-
tions by ISH using a digoxigenin–dUMP-labeled DNA
representing the complete WHV genome, with plasmid
pUC19 DNA serving as a control for hybridization spec-
ificity (Kajino et al., 1994); digoxigenin-labeled DNA was
detected using alkaline phosphatase-labeled anti-digoxi-
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genin–dUTP immunoglobulins, followed by detection
with 5-bromo-4-chloro-3-indolyl-phosphatase and ni-
troblue tetrazolium salt. The specific ISH signal, purple–
brown in color, is soluble in ethanol, so sections were
counterstained with hematoxylin and mounted in 25%
glycerol in PBS.
Histopathology was carried out on liver sections
stained with hematoxylin and eosin and liver injury was
graded on a subjective scale. Inflammation was the ma-
jor determinant with the other factors, hepatocyte necro-
sis, vacuolization, biliary hyperplasia, Kupffer cell activa-
tion, and variation in hepatocyte nuclear size, influencing
the degree of injury. A score was as follows: 0, no
evidence of liver injury; 1/2, scant numbers of inflam-
matory cells in portal tracts with minimal inflammation in
the liver parenchyma; 11, mild accumulations of lympho-
cytes in portal areas and focal accumulations in the
parenchyma, with individual hepatocyte necrosis,
Kupffer cell aggregates, and variation in hepatocyte nu-
clear size also present; 12, moderate inflammation of
portal tracts with sites of extension into the terminal
distributing vasculature; and 13, moderate to extensive
inflammatory infiltrate extending from the portal tract into
adjacent parenchyma or portal inflammation accompa-
nied by moderate to extensive parenchymal inflamma-
tion.
Serology
Serum samples were analyzed for g-glutamyl trans-
ferase (GGT) activity, as a marker of liver cancer progres-
sion (Abe et al., 1988), employing Vitros GGT slides
(Johnson & Johnson Clinical Diagnostics, Rochester, NY)
according to the manufacturer’s instructions. Results are
reported as standard international units per liter.
Concentrations of lamivudine in plasma samples
were determined, as previously described for the re-
lated 5-fluorinated compound (Frick et al., 1993, 1994),
in woodchucks that had been on therapy for at least 6
months.
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